Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 5/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 7/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 7/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 6/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5454736 | 0.83 | CNR2 (0.49) | CNR2KMT2ASMN1; SMN2 | |
| SCHEMBL14410968 | 0.80 | KCNH2 (0.50) | CNR2KMT2ASMN1; SMN2 | |
| SCHEMBL5452426 | 0.79 | DRD2 (0.46) | CNR2ADRA1DKMT2ASMN1; SMN2 | |
| SCHEMBL14411105 | 0.78 | CNR2 (0.50) | CNR2ADRA1DKMT2ASMN1; SMN2 | |
| SCHEMBL5448723 | 0.78 | MEN1 (0.59) | CNR2KMT2A | |
| SCHEMBL14411145 | 0.78 | OPRM1 (0.53) | OPRM1ADRA1DADRA1AADRA1BKMT2A | |
| SCHEMBL14410967 | 0.78 | DRD2 (0.52) | CNR2ADRA1BKMT2ASMN1; SMN2 | |
| SCHEMBL5444161 | 0.77 | ADRA1D (0.51) | CNR2ADRA1DADRA1AADRA1B | |
| SCHEMBL5451102 | 0.77 | CNR2 (0.54) | CNR2KMT2ASMN1; SMN2 | |
| SCHEMBL5453731 | 0.77 | CNR2 (0.48) | CNR2ADRA1DADRA1AKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | CNR2 106/4885OPRM1 217/4885ADRA1D 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.